AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31522562 — intervention group
Group type: EXPERIMENTAL
Intervention: High ratio between eGFRcystatin C and eGFRcreatinine
Number of subjects: 336
Study 31522562 — intervention group
Group type: EXPERIMENTAL
Intervention: High ratio between eGFRcystatin C and eGFRcreatinine in women
Number of subjects: 336
Study 31522562 — intervention group
Group type: EXPERIMENTAL
Intervention: High ratio between eGFRcystatin C and eGFRcreatinine in men
Number of subjects: 336
Study 31522562 — intervention group
Group type: EXPERIMENTAL
Intervention: High ratio between eGFRcystatin C and eGFRcreatinine in women with CAD
Number of subjects: 336
Study 31522562 — intervention group
Group type: EXPERIMENTAL
Intervention: High ratio between eGFRcystatin C and eGFRcreatinine in women without CAD
Number of subjects: 336
Study 30199861 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin Loaded Nanoemulsion (NE-TRE)
Number of subjects: 0
Study 30199861 — intervention group
Group type: COMPARATOR
Intervention: 0.05% Tretinoin Emulsion (Control)
Number of subjects: 0
Study 26861783 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin administration
Number of subjects: 91
Study 26861783 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic (4 weeks) empagliflozin administration
Number of subjects: 91
Study 26861783 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin in patients with T2D
Number of subjects: 91
Study 24717964 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV
Number of subjects: 300
Study 24717964 — intervention group
Group type: COMPARATOR
Intervention: SA14-14-2
Number of subjects: 300
Study 22458741 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine (T/A) single-pill combination (SPC)
Number of subjects: 858
Study 21126301 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular clinic services plus nine follow-up phone calls over 12 months
Number of subjects: 805
Study 21126301 — intervention group
Group type: COMPARATOR
Intervention: Regular clinic services
Number of subjects: 805
Study 17011678 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) injection of 0.1 ml dose of inactivated split‐virion influenza vaccine
Number of subjects: 500
Study 17011678 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) injection of 0.5 ml dose of inactivated split‐virion influenza vaccine
Number of subjects: 500
Study 15843666 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 600 mg weekly for one year
Number of subjects: 4012
Study 15843666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4012
Study 12415035 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching for ETS exposure reduction (7 coaching sessions, approximately 45 minutes each)
Number of subjects: 204
Study 12415035 — intervention group
Group type: COMPARATOR
Intervention: No additional service (control condition)
Number of subjects: 204
Study 10387506 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion program focusing on nutrition and physical activity over 16 weeks
Number of subjects: 34
Study 10387506 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion program
Number of subjects: 34
Study 10387506 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups feedback
Number of subjects: 34
Study 7569455 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 µg of estrogen and 300 µg of progestogen (Group 2)
Number of subjects: 371
Study 7569455 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 µg of estrogen and 500 µg of progestogen (Group 3)
Number of subjects: 371
Study 7569455 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 µg of levonorgestrel (Group 4)
Number of subjects: 371
Study 2169779 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg
Number of subjects: 296
Study 2169779 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 160 micrograms/kg
Number of subjects: 296
Study 2169779 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg (additional doses for breakthrough nausea)
Number of subjects: 296
Study 2169779 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40-240 micrograms/kg)
Number of subjects: 296
Study 6986949 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril, 100 mg orally
Number of subjects: 7
Study 6986949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31647036 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meals
Number of subjects: 8
Study 31647036 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meals
Number of subjects: 8
Study 27735931 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled hydrofluoalkane-beclomethasone dipropionate (QVAR) 100 μg per dose, twice daily via Aerochamber with face mask
Number of subjects: 38
Study 27735931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 25230894 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit exercise training (1 hour, three times a week for 12 weeks)
Number of subjects: 98
Study 25230894 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit exercise training
Number of subjects: 98
Study 25230894 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 98
Study 23949258 — intervention group
Group type: EXPERIMENTAL
Intervention: EHK02‐01 cream applied twice daily for 28 days
Number of subjects: 65
Study 23949258 — intervention group
Group type: COMPARATOR
Intervention: Control cream applied twice daily for 28 days
Number of subjects: 65
Study 22575040 — intervention group
Group type: EXPERIMENTAL
Intervention: L-alanylglutamine (AlaGln) at 89 mg/kg
Number of subjects: 8
Study 22575040 — intervention group
Group type: EXPERIMENTAL
Intervention: L-glutamine (L-Gln) at 60 mg/kg
Number of subjects: 8
Study 22575040 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatically hydrolyzed wheat protein (HWP) at 200 mg/kg
Number of subjects: 8
Study 22575040 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 8
Study 19412108 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.03‐0.1 microg kg min)
Number of subjects: 50
Study 19412108 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1‐3 microg kg) and midazolam (0.05‐0.1 mg kg)
Number of subjects: 50
Study 17380360 — intervention group
Group type: EXPERIMENTAL
Intervention: Power water‐assisted liposuction
Number of subjects: 60
Study 17380360 — intervention group
Group type: COMPARATOR
Intervention: Traditional liposuction
Number of subjects: 60
Study 15356368 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide antimicrobial gauze
Number of subjects: 21
Study 15356368 — intervention group
Group type: COMPARATOR
Intervention: Control gauze without polyhexamethylene biguanide
Number of subjects: 21
Study 12355937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus irinotecan for advanced non-small cell lung cancer
Number of subjects: 0
Study 12355937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus docetaxel for advanced non-small cell lung cancer
Number of subjects: 0
Study 12355937 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus irinotecan for small cell lung cancer
Number of subjects: 0
Study 12355937 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy for localized disease of both small and non-small cell lung cancers
Number of subjects: 0
Study 12355937 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant treatment methods for resected patients
Number of subjects: 0
Study 9651406 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (10 microg/kg/d)
Number of subjects: 20
Study 9651406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8016028 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple risk factor intervention over 2 years
Number of subjects: 25000
Study 8016028 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite as the unit of randomization and intervention
Number of subjects: 25000
Study 8016028 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the transtheoretical stage of change model
Number of subjects: 25000
Study 8016028 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer resources within the worksite
Number of subjects: 25000
Study 2687423 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil
Number of subjects: 0
Study 2687423 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 0
Study 2687423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1097925 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 to 320 mg per day for six and 12 weeks)
Number of subjects: 20
Study 1097925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31326727 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide/metformin
Number of subjects: 41
Study 31326727 — intervention group
Group type: COMPARATOR
Intervention: placebo/metformin
Number of subjects: 41
Study 27878354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab alone (Cet group)
Number of subjects: 29
Study 27878354 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab and irinotecan (CetI group)
Number of subjects: 29
Study 24927926 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU)
Number of subjects: 71
Study 24927926 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71
Study 23155151 — intervention group
Group type: EXPERIMENTAL
Intervention: boceprevir (800 mg, 3 times daily) for 6 days followed by atazanavir (300 mg once daily) with ritonavir (100 mg) on days 10-31, plus concomitant boceprevir on days 25-31
Number of subjects: 39
Study 23155151 — intervention group
Group type: EXPERIMENTAL
Intervention: boceprevir (800 mg, 3 times daily) for 6 days followed by lopinavir (400 mg twice daily) with ritonavir (100 mg) on days 10-31, plus concomitant boceprevir on days 25-31
Number of subjects: 39
Study 23155151 — intervention group
Group type: EXPERIMENTAL
Intervention: boceprevir (800 mg, 3 times daily) for 6 days followed by darunavir (600 mg twice daily) with ritonavir (100 mg) on days 10-31, plus concomitant boceprevir on days 25-31
Number of subjects: 39
Study 23155151 — intervention group
Group type: EXPERIMENTAL
Intervention: boceprevir (800 mg, 3 times daily)
Number of subjects: 39
Study 23155151 — intervention group
Group type: COMPARATOR
Intervention: ritonavir (100 mg)
Number of subjects: 39
Study 21602430 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 10
Study 21602430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19672236 — intervention group
Group type: EXPERIMENTAL
Intervention: Acatinol (10 mg daily)
Number of subjects: 60
Study 19672236 — intervention group
Group type: COMPARATOR
Intervention: Piracetam (1200 mg daily)
Number of subjects: 60
Study 16968405 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (LcS) fermented milk, 4 x 10(10) live LcS for 3 weeks
Number of subjects: 0
Study 16968405 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-killed LcS
Number of subjects: 0
Study 16968405 — intervention group
Group type: COMPARATOR
Intervention: Anti-IL-12 monoclonal antibody
Number of subjects: 0
Study 16968405 — intervention group
Group type: EXPERIMENTAL
Intervention: Separation of NK cells from LcS-stimulated monocytes
Number of subjects: 0
Study 16281467 — intervention group
Group type: EXPERIMENTAL
Intervention: Salk Polio Vaccine
Number of subjects: 1800000
Study 16281467 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1800000
Study 11176469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscopy via a 12-14Fr ureteral access sheath
Number of subjects: 59
Study 11176469 — intervention group
Group type: COMPARATOR
Intervention: Unaided ureteroscopy with no access sheath
Number of subjects: 59
Study 11176469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteral access sheath used as a dilator
Number of subjects: 59
Study 11176469 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 18Fr ureteral balloon dilator
Number of subjects: 59
Study 11176469 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall costs and operative time with access sheath
Number of subjects: 59
Study 9250112 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-sufficient group (normal iron status)
Number of subjects: 30
Study 9250112 — intervention group
Group type: COMPARATOR
Intervention: Iron-depleted group
Number of subjects: 30
Study 8280654 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 40 mg daily
Number of subjects: 184
Study 8280654 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 160 mg daily
Number of subjects: 184
Study 8280654 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Tamoxifen and Megestrol acetate
Number of subjects: 184
Study 8280654 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 184
Study 2879457 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium entry blocker (nitrendipine)
Number of subjects: 40
Study 2879457 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta adrenoreceptor blocker (oxprenolol)
Number of subjects: 40
Study 31829907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganetespib 150 mg/m2 on days 1 and 15 with docetaxel 75 mg/m2 on day 1 of a 21-day cycle
Number of subjects: 677
Study 31829907 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 677
Study 31829907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganetespib and docetaxel
Number of subjects: 677
Study 29936130 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive image-guided breast brachytherapy (NIBB) with a total dose of 28.5 Gy in five daily fractions.
Number of subjects: 40
Study 27904925 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit Less
Number of subjects: 19
Study 27904925 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 19
Study 27904925 — intervention group
Group type: COMPARATOR
Intervention: Sitting
Number of subjects: 19
Study 24902881 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva Manoeuvre (VM) in supine posture
Number of subjects: 72
Study 24902881 — intervention group
Group type: COMPARATOR
Intervention: Valsalva Manoeuvre (VM) in Trendelenberg posture
Number of subjects: 72
Study 24902881 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Dive Reflex Manoeuvre (HDR) in supine posture
Number of subjects: 72
Study 24902881 — intervention group
Group type: COMPARATOR
Intervention: Human Dive Reflex Manoeuvre (HDR) in sitting posture
Number of subjects: 72
Study 23139021 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-delivered cognitive behavioural therapy for 8 weeks
Number of subjects: 72
Study 23139021 — intervention group
Group type: COMPARATOR
Intervention: Moderated online discussion forum (Control)
Number of subjects: 72
Study 20477925 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (400 mg five times a day for 1 week)
Number of subjects: 64
Study 20477925 — intervention group
Group type: COMPARATOR
Intervention: Follow-up
Number of subjects: 64
Study 18565240 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epoetin beta (6000 IU weekly for 2 weeks)
Number of subjects: 48
Study 18565240 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous darbepoetin alfa (30 mug weekly for 2 weeks)
Number of subjects: 48
Study 18565240 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference for treatment
Number of subjects: 48
Study 16648085 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment based on acupuncture diagnosis
Number of subjects: 0
Study 16648085 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized treatments
Number of subjects: 0
Study 16648085 — intervention group
Group type: COMPARATOR
Intervention: Blinding in RCTs
Number of subjects: 0
Study 16648085 — intervention group
Group type: COMPARATOR
Intervention: Sham techniques
Number of subjects: 0
Study 12771834 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based rehabilitation provided by outpatient physical therapists
Number of subjects: 160
Study 12771834 — intervention group
Group type: COMPARATOR
Intervention: Home-based rehabilitation monitored by periodic telephone calls from a physical therapist
Number of subjects: 160
Study 10837296 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-lactalbumin diet
Number of subjects: 29
Study 10837296 — intervention group
Group type: COMPARATOR
Intervention: sodium-caseinate diet
Number of subjects: 29
Study 9176531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural streptokinase, 250,000 i.u. daily for three days
Number of subjects: 24
Study 9176531 — intervention group
Group type: COMPARATOR
Intervention: Control saline flushes for three days
Number of subjects: 24
Study 1545974 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine intra‐alveolar dressings
Number of subjects: 70
Study 1545974 — intervention group
Group type: COMPARATOR
Intervention: Saline solution intra‐alveolar dressings
Number of subjects: 70
Study 2865718 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 2865718 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 0
Study 30340935 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (≥12 months)
Number of subjects: 660
Study 30340935 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial insurance
Number of subjects: 660
Study 30340935 — intervention group
Group type: COMPARATOR
Intervention: Race, ethnicity, primary caregiver's education level, and income
Number of subjects: 660
Study 30517038 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging at 2500m for 2 days
Number of subjects: 65
Study 30517038 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging at 3000m for 2 days
Number of subjects: 65
Study 30517038 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging at 3500m for 2 days
Number of subjects: 65
Study 30517038 — intervention group
Group type: COMPARATOR
Intervention: Direct ascent to 4300m (Control)
Number of subjects: 65
Study 30517038 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging at 2500m
Number of subjects: 65
Study 30517038 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging at 3000m
Number of subjects: 65
Study 30517038 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging at 3500m
Number of subjects: 65
Study 26406287 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT + TME (5 × 5 Gy)
Number of subjects: 1530
Study 26406287 — intervention group
Group type: COMPARATOR
Intervention: TME alone
Number of subjects: 1530
Study 24468539 — intervention group
Group type: EXPERIMENTAL
Intervention: Old age
Number of subjects: 100
Study 24468539 — intervention group
Group type: EXPERIMENTAL
Intervention: Low triglyceride
Number of subjects: 100
Study 24468539 — intervention group
Group type: EXPERIMENTAL
Intervention: Periventricular WMC (PVWMC)
Number of subjects: 100
Study 24468539 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of thalamic microbleed
Number of subjects: 100
Study 23176989 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine soaked in Gelfoam(®)
Number of subjects: 0
Study 23176989 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study 20231185 — intervention group
Group type: EXPERIMENTAL
Intervention: Public disclosure process via brochure and poster in PICU waiting rooms
Number of subjects: 93
Study 20231185 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure
Number of subjects: 93
Study 20231185 — intervention group
Group type: EXPERIMENTAL
Intervention: Poster
Number of subjects: 93
Study 20231185 — intervention group
Group type: EXPERIMENTAL
Intervention: Public disclosure process
Number of subjects: 93
Study 20231185 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out option awareness
Number of subjects: 93
Study 17384010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensively treated patients after stabilization of glycemia (from 6 months onward)
Number of subjects: 11727
Study 17384010 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensively treated patients at baseline
Number of subjects: 11727
Study 17384010 — intervention group
Group type: COMPARATOR
Intervention: Conventionally treated patients from 6 months onward
Number of subjects: 11727
Study 16353046 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg) with hydrochlorothiazide (25 mg)
Number of subjects: 60
Study 16353046 — intervention group
Group type: COMPARATOR
Intervention: Captopril (50 mg) with hydrochlorothiazide (25 mg)
Number of subjects: 60
Study 16923694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod liver oil (n-3 PUFAs)
Number of subjects: 590
Study 16923694 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (n-6 PUFAs)
Number of subjects: 590
Study 10924001 — intervention group
Group type: EXPERIMENTAL
Intervention: d,l‐fenfluramine (100 mg orally)
Number of subjects: 110
Study 10924001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 8638784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 214
Study 8638784 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 214
Study 1387512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) 40 micrograms via Ingelheim powder device (IPI)
Number of subjects: 70
Study 1387512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) 40 micrograms via metered dose inhaler (MDI)
Number of subjects: 70
Study 1387512 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide (IB) 40 micrograms
Number of subjects: 70
Study 1387512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (not specified dosage)
Number of subjects: 70
Study 6516414 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline administered in aqueous solution
Number of subjects: 0
Study 6516414 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 0
Study 6516414 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline oral preparations
Number of subjects: 0
Study 6516414 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of Theophylline
Number of subjects: 0
Study 31187518 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 394